欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2025, Vol. 30 ›› Issue (10): 1312-1318.doi: 10.12092/j.issn.1009-2501.2025.10.003

• “术后疼痛管理前沿及进展”专栏 • 上一篇    下一篇

不同时机应用羟考酮对胸科手术肋间神经阻滞消退后反跳痛防治效果的临床研究

蒋露香,张建友,张转,郭淼,唐苏红   

  1. 扬州大学附属医院麻醉科,扬州  225000,江苏
  • 收稿日期:2024-09-06 修回日期:2025-02-18 出版日期:2025-10-26 发布日期:2025-10-15
  • 通讯作者: 唐苏红,女,硕士,主任医师,研究方向:临床麻醉。 E-mail:tshgmz@126.com
  • 作者简介:蒋露香,女,主治医师,研究方向:临床麻醉。 E-mail:1591984955@qq.com
  • 基金资助:
    江苏省科技厅社会发展面上项目(BE2023749)

A clinical study on the preventive and therapeutic effects of oxycodone administered at different timings on rebound pain following the wearing off of intercostal nerve block in thoracic surgery

JIANG Luxiang, ZHANG Jianyou, ZHANG Zhuan, GUO Miao, TANG Suhong   

  1. Department of Anesthesiology Affiliated Hospital of Yangzhou University, Yangzhou 225000, Jiangsu, China
  • Received:2024-09-06 Revised:2025-02-18 Online:2025-10-26 Published:2025-10-15

摘要:

目的:评价不同时机静脉应用羟考酮对胸腔镜手术肋间神经阻滞消退后反跳痛的影响。方法:选择2024年1 月至7月择期全麻下行胸腔镜手术患者114例,年龄18~64 岁,性别不限,BMI 18~30 kg/m2,ASA Ⅰ-Ⅱ级。采用随机数字表法将患者分为三组:对照组(C组),术毕静注羟考酮组(Q1组)和术后6 h静注羟考酮组(Q2组),每组38例。C组术毕静注生理盐水,Q1组术毕静注羟考酮0.04 mg/kg,Q2组术后6 h静注羟考酮0.04 mg/kg。三组患者采用术后静脉自控镇痛泵(PCIA)。记录术后反跳痛的发生情况,记录首次按压镇痛泵时间、按压次数、舒芬太尼用量和补救镇痛情况;记录术后6、8、12、24、48、72 h静息和运动时的数字疼痛评分(NRS);采用匹兹堡睡眠质量指数(PSQI)评估患者术前一晚和术后两晚的睡眠质量;记录术后呼吸抑制、恶心呕吐(PONV)、嗜睡和瘙痒等不良反应情况。结果:与C组和Q1组相比,Q2组反跳痛发生率、术后舒芬太尼消耗量、术后0~24 h PCIA有效按压次数和补救镇痛率降低,差异具有统计学意义(P<0.05);与C组比较,Q1和Q2组在术后8、12、24 h的静息及运动NRS评分均明显降低,差异具有统计学意义(P<0.05);与Q1组相比,Q2组在术后8、12、24 h的静息及运动NRS评分较低,差异具有统计学意义(P<0.05)。术后第一晚,Q2组患者的PSQI评分较C组和Q1组显著改善(P<0.05)。三组患者PONV发生率差异无统计学意义(P>0.05)。三组患者术后均未见呼吸抑制、嗜睡及瘙痒等不良反应发生。结论:术后6 h静注0.04 mg/kg的羟考酮可降低胸腔镜手术肋间神经阻滞消退后反跳痛的发生,改善患者睡眠质量。

关键词: 反跳痛, 胸腔镜手术, 肋间神经阻滞, 羟考酮

Abstract:

AIM: To evaluate the effect of intravenous oxycodone administration at different timing on rebound pain following the resolution of intercostal nerve blockade after thoracoscopic surgery. METHODS: A total of 114 patients undergoing elective thoracoscopic surgery under general anesthesia between January and July 2024 were selected. The patients were aged 18 to 64 years, regardless of gender, with a BMI of 18 to 30 kg/m2, and classified as ASA I-II. The patients were randomly divided into three groups using a random number table: control group (Group C), oxycodone administration at the end of surgery group (Group Q1), and oxycodone administration 6 hours postoperatively group (Group Q2), with 38 patients in each group. Group C received a normal saline injection at the end of surgery, Group Q1 received an intravenous injection of oxycodone 0.04 mg/kg at the end of surgery, and Group Q2 received an intravenous injection of oxycodone 0.04 mg/kg at 6 hours postoperatively. Patients in the three groups were treated with a postoperative intravenous self-control analgesic pump (PCIA). The occurrence of rebound pain was recorded, the time of the first analgesic pump press, the number of presses, the dosage of sufentanil, and the need for rescue analgesia were also recorded. Numerical Rating Scale (NRS) scores at rest and during movement were recorded at 6, 8, 12, 24, 48 and 72 hours postoperatively. The Pittsburgh Sleep Quality Index (PSQI) was used to assess the sleep quality of patients the night before surgery and for two nights postoperatively. Adverse reactions such as respiratory depression, postoperative nausea and vomiting (PONV), and pruritus were recorded. RESULTS: Compared with group C and Q1, the incidence of rebound pain, postoperative sufentanil consumption, effective compression frequency of PCIA from 0-24 hours after surgery, and the rate of rescue analgesia were lower in Groups Q2 (P<0.05); Compared to Group C, the NRS scores at rest and during movement at 8, 12, and 24 hours postoperatively were significantly lower in Groups Q1 and Q2 (P<0.05). However, compared to Group Q1, Group Q2 exhibited lower NRS scores at rest and during movement at 8, 12, and 24 hours postoperatively (P<0.05). On the first postoperative night, the PSQI scores of patients in Group Q2 were significantly better than those in Groups C and Q1 (P<0.05). There was no statistically significant difference in the incidence of PONV among the three groups (P>0.05). No respiratory depression, drowsiness, or pruritus were observed postoperatively in any of the groups. CONCLUSION: Intravenous injection of 0.04 mg/kg oxycodone 6 hours after surgery can reduce the occurrence of rebound pain after intercostal nerve block resolution in thoracoscopic surgery and improves patients' sleep quality.

Key words: rebound pain, thoracoscopic surgery, intercostal nerve block, oxycodone

中图分类号: